CA2405136C - Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents - Google Patents

Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents Download PDF

Info

Publication number
CA2405136C
CA2405136C CA002405136A CA2405136A CA2405136C CA 2405136 C CA2405136 C CA 2405136C CA 002405136 A CA002405136 A CA 002405136A CA 2405136 A CA2405136 A CA 2405136A CA 2405136 C CA2405136 C CA 2405136C
Authority
CA
Canada
Prior art keywords
compound
treatment
accordance
compounds
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002405136A
Other languages
English (en)
French (fr)
Other versions
CA2405136A1 (en
Inventor
Alissar Nehme
Richard L. Beard
Roshantha A. Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Therapeutics Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2405136A1 publication Critical patent/CA2405136A1/en
Application granted granted Critical
Publication of CA2405136C publication Critical patent/CA2405136C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002405136A 2000-04-04 2001-04-02 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents Expired - Lifetime CA2405136C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54214800A 2000-04-04 2000-04-04
US09/542,148 2000-04-04
PCT/US2001/010410 WO2001074759A1 (en) 2000-04-04 2001-04-02 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents

Publications (2)

Publication Number Publication Date
CA2405136A1 CA2405136A1 (en) 2001-10-11
CA2405136C true CA2405136C (en) 2009-06-16

Family

ID=24162539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405136A Expired - Lifetime CA2405136C (en) 2000-04-04 2001-04-02 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents

Country Status (10)

Country Link
US (1) US6387950B2 (enExample)
EP (2) EP1268405B1 (enExample)
JP (1) JP2003534246A (enExample)
AT (1) ATE331703T1 (enExample)
AU (1) AU2001253045A1 (enExample)
CA (1) CA2405136C (enExample)
DE (1) DE60121145T2 (enExample)
ES (1) ES2267754T3 (enExample)
TW (1) TWI281911B (enExample)
WO (1) WO2001074759A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903121B1 (en) * 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
EP1935869A1 (en) * 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
WO2002028810A2 (en) * 2000-10-02 2002-04-11 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
US6620963B1 (en) 2002-09-19 2003-09-16 Allergan, Inc. TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
WO2005093426A2 (en) * 2004-03-26 2005-10-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)
LT1937244T (lt) 2005-09-30 2018-11-12 Io Therapeutics, Llc Vėžio gydymas specifiniais rxr agonistais
EP2685972A4 (en) * 2011-03-14 2014-08-13 Io Therapeutics Inc TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
EP3277272B1 (en) 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-agonists
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
NZ745704A (en) 2016-03-10 2019-04-26 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
KR20240157122A (ko) 2016-04-08 2024-10-31 사이로스 파마수티컬스, 인크. Aml 및 mds 치료용 rara 효능제
CA3069672A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3684348A4 (en) 2017-09-20 2021-08-18 IO Therapeutics, Inc. TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
EP4444287A4 (en) 2021-12-07 2025-05-28 Io Therapeutics, Inc. USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
CN114703227B (zh) * 2022-01-27 2023-11-10 中国科学院生态环境研究中心 基于MCF-7细胞系构建的RARα效应物体外筛选方法
CN119451672A (zh) 2022-06-27 2025-02-14 Io治疗公司 四氢萘酚的合成及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE617614T1 (de) * 1991-12-18 1995-06-08 Baylor College Of Medicine, Houston, Tex. Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.
US5675024A (en) * 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity

Also Published As

Publication number Publication date
CA2405136A1 (en) 2001-10-11
WO2001074759A1 (en) 2001-10-11
US20010039293A1 (en) 2001-11-08
AU2001253045A1 (en) 2001-10-15
EP1268405A1 (en) 2003-01-02
ATE331703T1 (de) 2006-07-15
TWI281911B (en) 2007-06-01
ES2267754T3 (es) 2007-03-16
US6387950B2 (en) 2002-05-14
EP1268405B1 (en) 2006-06-28
JP2003534246A (ja) 2003-11-18
DE60121145D1 (de) 2006-08-10
EP1650188A1 (en) 2006-04-26
DE60121145T2 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
EP1268405B1 (en) Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
Göttlicher et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Mehndiratta et al. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression
US8101793B2 (en) Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
US8389538B2 (en) Rexinoid compound having alkoxy group
Simoni et al. Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells
RU2364589C2 (ru) Ингибиторы гистондезацетилазы из новых производных бензамида с сильной дифференцировочной и антипролиферативной активностью
JP4188416B2 (ja) 有意なホルモン活性のないチロキシン類縁体による悪性腫瘍の治療方法
AU2001230929B2 (en) Aniline-derived ligands for the thyroid receptor
Teng et al. Identification of a retinoic acid receptor α subtype specific agonist
He et al. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer
CN1513839A (zh) 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
US11312680B2 (en) Method for treating a patient having a colon cancer
Mori et al. Development of retinoic acid receptor antagonists bearing trans-SF4-alkynyl structure as a linear linker
HK1091196A (en) Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
US5703130A (en) Chalcone retinoids and methods of use of same
CN100455564C (zh) 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
AU702423B2 (en) Chalcone retinoids and methods of use of same
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
Pfahl Retinoid related molecules: new promises against lung and breast cancer
US20070123592A1 (en) Terephthalamide peptidomimetic compounds and methods
EP1383491A2 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210406